Equibles does not estimate personal net worth.
Get an email with a short summary when TherapeuticsMD, Inc. publishes a filing, an earnings call transcript or a press release.
Get TXMD alertsBrian Bernick is recorded as CEO at TherapeuticsMD, Inc. (TXMD) since September 6, 2022. TherapeuticsMD, Inc. reported in an 8-K filed September 12, 2022 that Brian Bernick was appointed Interim Co-Chief Executive Officer, effective September 6, 2022. The proxy statement of TherapeuticsMD, Inc. reports total compensation of $1,624,016 for Brian Bernick in fiscal 2022, including a base salary of $500,000. TherapeuticsMD, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at TherapeuticsMD, Inc. includes Mark Glickman (CEO), Marlan D. Walker (CEO and General Counsel), Robert Finizio (CEO and Board Member) and 7 others.
“On September 6, 2022, the board of directors (the "Board") of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), appointed Dr. Brian Bernick, the Company's co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company's Chief Business Officer, as the Company's Interim Co-Chief Executive Officers and co-principal executive officers.”
2022-09-06–present
Proxy statement
Start not stated–2021-04-14
Last confirmed by a filing; no departure on record
TXMD
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
2022-09-06–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | TherapeuticsMD, Inc. (TXMD) | Former Interim Co-Chief Executive Officer | $500,000 | $1,624,016 |
